文献速递腹部泌尿生殖CTMRPET

肾细胞癌多模态分期:要点与陷阱

Multimodality staging of renal cell carcinoma-pearls & pitfalls.
PubMed 文献 · Abdom Radiol (NY) · 2026-07-06

本文是一篇教育性综述,围绕肾细胞癌的多模态影像分期展开,重点讨论CT与MRI在局部分期中的价值及常见解读陷阱。文章强调肾窦侵犯、肾周侵犯、下腔静脉壁受累及邻近器官侵犯易被高估或低估,并提出了结构化报告建议以改善多学科沟通。

要点

  • 肾窦、肾周、静脉壁及邻近器官侵犯易高估或低估,直接影响治疗决策
  • 动脉期成像对疑诊透明细胞肾癌有帮助,MRI可用于局部分期困难病例
  • 淋巴结、肺结节、骨髓转移及不典型转移灶易导致分期误判

核心结论

  • 肾细胞癌分期的影像解读差异可改变手术规划、系统治疗选择及预后判断
  • 增强CT和MRI是局部分期的基础,可评估肿瘤大小、肾窦与肾周扩展、静脉癌栓及筋膜外侵犯
  • 结构化报告有助于提高完整性、一致性及多学科沟通效率

研究设计与样本

  • 教育性综述,围绕肾细胞癌多模态分期、解读陷阱及报告策略展开
  • 重点评价增强CT、MRI在局部分期中的作用及易误判特征

关键影像表现/征象

  • 肾窦侵犯、肾周侵犯、下腔静脉壁受累及邻近器官侵犯是常见高估或低估的影像征象
  • 淋巴结评估受反应性增大与转移性病变重叠影响
  • 不确定的肺结节、骨髓来源骨转移及不典型转移部位可增加解读难度

诊断标准与关键数值

  • 增强CT与MRI为局部分期的基础手段,用于评估肿瘤大小、肾窦与肾周扩展、静脉癌栓及筋膜外侵犯
  • 动脉期成像对疑诊透明细胞肾癌有价值,MRI在局部分期不明确时具有补充作用
  • PET及新型靶向示踪剂在肾细胞癌分期中为选择性应用而非常规

临床应用与阅片要点

  • 阅片时应特别警惕肾窦与肾周侵犯、静脉壁受累及邻近器官侵犯的过判与漏判
  • 对局部分期不明确的病例可考虑MRI补充评估
  • 报告应突出与管理相关的影像征象,并采用结构化格式以利于多学科沟通

局限性

  • 淋巴结评估受反应性增大与转移性病变重叠限制
  • 不确定肺结节、骨髓转移及不典型转移部位可能影响分期准确性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Accurate staging of renal cell carcinoma (RCC) is critical because small differences in imaging interpretation can alter operative planning, systemic treatment decisions, and prognosis. This educational review highlights the practical role of multimodality imaging in RCC staging, with emphasis on common interpretive pitfalls and reporting strategies that improve clinical decision-making. Contrast-enhanced CT and MRI remain the foundation of local staging, enabling assessment of tumour size, renal sinus and perinephric extension, venous tumour thrombus, and spread beyond the perinephric fascia. However, several features are prone to overcall or undercall, particularly renal sinus invasion, perinephric invasion, inferior vena cava wall involvement, and adjacent organ invasion, with direct implications for management. Regional and distant staging are likewise imperfect. Nodal assessment remains limited by the overlap between reactive enlargement and metastatic disease, while indeterminate pulmonary nodules, marrow-based bone metastases, and atypical metastatic sites may all complicate interpretation. Selected technical considerations, including the potential value of arterial phase imaging in suspected clear cell RCC and the problem-solving role of MRI in equivocal local staging, may help reduce understaging. The role of PET and emerging targeted tracers remains selective rather than routine. Throughout, emphasis is placed on management-relevant imaging findings, modality-specific strengths and weaknesses, and practical pearls derived from experience. A structured reporting approach is also proposed to improve completeness, consistency, and communication with the multidisciplinary team.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Withey, Otero-Garcia, Aymerich, et al. Multimodality staging of renal cell carcinoma-pearls & pitfalls. Abdom Radiol (NY). 2026. PMID: 42406034. doi:10.1007/s00261-026-05660-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。